Incyte stands to benefit from unveiling data on its cancer treatments at a conference in the coming days, a biotech analyst said.» Read More
Scientists say if no action is taken during California's extreme drought, there could be dire and irreversible consequences for wildlife.
While there are weaknesses in the alternative market of prescription drugs, the risks are not always as serious as some claim.
Internet drugstores and their facilitators may claim to be safe, low-cost alternatives to pharmacies. But consumers need to be cautious.
The largest U.S. pharmacy benefit manager, Express Scripts, is cutting back on compounded medications, saying most are ineffective or overpriced.
Hedge fund Paulson & Co has amassed a large stake in Allergan and is supportive of a deal between the Botox maker and Valeant Pharmaceuticals.
New York leaders have reached an agreement to legalize medical marijuana in New York.
As the global population ages, some see investment opportunities in somewhat ghoulish bets the rates of cancer and other illnesses will rise.
CNBC's Andrea Day looks into the FBI's investigation of the Los Zetas drug cartel, which used horse racing to launder money.
Orexigen Therapeutics said the FDA delayed a decision on its obesity drug by three months, sending the company's shares down about 19 percent.
But Merck chief Kenneth Frazier also said the government needs to modify its high corporate tax code to level the playing field for American companies.
Chicago filed a lawsuit against five pharmaceutical companies, accusing them of concealing the risks associated with certain painkillers.
Patients can try new once-a-day tablets that dissolve quickly under the tongue and raise tolerance to grass or ragweed pollen, much like the shots.
The announcement that GSK is planning to spend $350 million plus to get a slice of a U.K. biotech's cancer drugs has raised eyebrows.
This year's biggest cancer conference begins tomorrow. CNBC's Meg Tirrell reports why immunotherapy drugs will be a key theme with drug makers at ASCO.
GSK has invited private equity firms to consider making offers for a range of its older drugs, three people with direct knowledge of the matter said.
CNBC's Meg Tirrell reports shares of PTC Therapeutics are surging on a recommendation of the drug "Ataluren" designed to treat Duchenne muscular dystrophy which could be a billion dollar drug.
Pfizer's pursuit of AstraZeneca raises a huge public policy red flag, writes Andrew Ross Sorkin in the New York Times.
Colombian Finance Minister Mauricio Cárdenas Santamaria says resolving the country's drugs issue will help the country post stronger growth.
CNBC's Meg Tirrell speaks with George Scangos, Biogen Idec CEO, about the drug maker's fight against MS and Alzheimer's. Scangos also comments on Valeant's bid for Alllergan.
Drugmakers eager to satisfy shareholders are wheeling, dealing, and in one case even making trades like a pro sports team looking to shake up its roster.